News|Articles|June 18, 2026

ZEISS reports early implantations of AT LUCIA Toric 721P IOL in Europe

Fact checked by: Martin David Harp

The CE-marked lens is being placed by selected surgeons across 6 European countries under a company-described early-access program

Carl Zeiss Meditec has reported the first clinical implantations of the AT LUCIA toric 721P, a single-piece hydrophobic acrylic toric intraocular lens (IOL) designed to correct corneal astigmatism during cataract surgery.¹ The CE-marked lens is being placed by selected surgeons across 6 European countries under a company-described early-access program, with commercial availability in some European markets expected later in 2026.¹

For surgeons, the news marks a product launch rather than a release of clinical evidence. No peer-reviewed outcomes, registered trial record, or regulatory efficacy review specific to the 721P have been published; the accompanying surgeon statements reflect early intraoperative impressions, not measured endpoints.¹

The lens addresses a real gap. Roughly 30% to 40% of cataract surgery candidates present with at least 1.0 D of corneal astigmatism, and toric IOLs are the principal intraocular option for correcting it.² The defining performance metric is rotational stability: misalignment of about 1° reduces astigmatic correction by approximately 3.3%, and a 30° deviation can negate the toric effect entirely.³ The company's "stability" messaging is clinically meaningful only with postoperative rotation data, which are not yet available.

The 721P extends the LUCIA platform—a hydrophobic, C-loop, single-piece design built around the patented ZO non-constant-aberration aspheric optic—into the toric category.⁴ This represents an architectural shift from ZEISS's existing plate-haptic, four-point-fixation toric lenses (AT TORBI, AT LARA toric, AT LISA tri toric); whether a C-loop toric matches their rotational stability is an open question.⁵

Clinicians should note the regulatory framing: CE marking under the EU Medical Device Regulation is a conformity assessment, not an FDA premarket approval, and as a device, the lens falls outside the EMA's remit. No US availability has been announced.

References:
  1. ZEISS Medical Technology. First implantations of the AT LUCIA toric 721P IOL [press release]. PR Newswire. June 11, 2026. https://www.prnewswire.com/news-releases/zeiss-announces-successful-early-implantations-of-the-at-lucia-toric-721p-intraocular-lens-302797358.html
  2. Prevalence of corneal astigmatism before cataract surgery. Int Ophthalmol. 2016. https://link.springer.com/article/10.1007/s10792-016-0201-z
  3. Toric intraocular lenses. StatPearls. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK592396/
  4. Early clinical experience with the CT LUCIA 621P monofocal IOL. Clin Ophthalmol. https://pmc.ncbi.nlm.nih.gov/articles/PMC10655610/
  5. ZEISS Toric IOL family (AT TORBI, AT LARA toric, AT LISA tri toric). Carl Zeiss Meditec AG. https://www.zeiss.com/meditec/en/products/iols/toric-iols/toric-iol-family.html

Latest CME